Compare GSK plc (GSK) vs Rivian Automotive, Inc. (RIVN) Price & Performance

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Rivian (RIVN) trades at $16.015, down 2.29% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $5.0B in 2024 to $5.4B in 2025, though net losses persist at -$3.65B. Recent R2 vehicle launches and raised 2026 delivery guidance to 65,000-70,000 vehicles indicate operational progress. Analyst consensus is mixed with 48% buy ratings and a $18.70 price target, suggesting 17% upside potential from current levels.

Rivian presents a high-risk growth opportunity with significant cash burn ($1.72B net outflow in 2025) but improving margin trends. The R2 ramp-up and Uber partnership offer catalysts, though execution risks and EV market competition remain concerns. With negative profitability metrics and substantial debt, the stock suits investors comfortable with early-stage company volatility seeking EV market exposure.